

Supporting Information

Copper-Catalyzed Cross-Coupling Reactions of Epoxides with *gem*-Diborylmethane: Access to γ -Hydroxyl Boronic Esters

Table of Contents

I. General Information.....	S2
II. Preparation of Substrates.....	S3-S7
III. General Experimental Procedures, Spectral Data and HPLC Analysis.....	S7-S15
IV. References.....	S16
V. NMR Spectra.....	S17-S41

I. General Information

a). Materials

All the reactions were carried out in oven-dried schlenk tubes under argon atmosphere (purity \geq 99.999%). Copper(I) iodide was purchased from Sinopharm Chemical Reagent Co., Ltd as an off-white powder (which refluxed in THF for 8 hrs in soxhlet extractor, the resulting mixture was filtered through Buchner funnel and dried under vacuum).¹ The following chemicals were purchased and used as received: LiO-*t*Bu (Acros, 99.9%), KO-*t*Bu (Acros), NaO-*t*Bu (Acros), 2-(phenoxy)methyl)oxirane (adamas, 98%), (S)-2-((benzyloxy)methyl)oxirane (adamas, 98%), 2-((benzyloxy)methyl)oxirane (adamas, 98%), 2-phenyloxirane (adamas, 98%).

Anhydrous solvents (CH₃CN, DMF, 1, 4-dioxane, THF) were purchased from Acros and used without further purification. Anhydrous THF (Acros) was stored over 4 Å molecular sieves under an argon atmosphere in a septum-capped bottle.

All the other reagents and solvents mentioned in this text were purchased from commercial sources and used without purification.

b). Analytical Methods

¹H-NMR, ¹³C-NMR and ¹⁹F-NMR spectra were recorded on a Bruker Avance 400 spectrometer at ambient temperature in CDCl₃ unless otherwise noted; Data for ¹H-NMR are reported as follows: chemical shift (δ ppm), multiplicity, integration, and coupling constant (Hz). Data for ¹³C-NMR are reported in terms of chemical shift (δ ppm), multiplicity, and coupling constant (Hz). Gas chromatographic (GC) analysis was acquired on a Shimadzu GC-2014 Series GC System equipped with a flame-ionization detector. GC-MS analysis was performed on Thermo Scientific AS 3000 Series GC-MS System. HRMS analysis was performed on FinniganLCQ advantage Max Series MS System. HPLC analysis was performed on Waters-Breeze (2487 Dual Absorbance Detector and 1525 Binary HPLC Pump). Chiralpak IC, OD, AS, KM columns were purchased from Daicel Chemical Industries, LTD. Organic solutions were concentrated under reduced pressure on a Buchi rotary evaporator. Flash column chromatographic purification of products was accomplished using forced-flow chromatography on Silica Gel (200-300 mesh).

II. Preparation of Substrates


a). Synthesis of bis(boronates)

1,1-diborylmethane was prepared according to literature procedure,² and NMR data have reported there.

b). Synthesis and characterization of epoxides


(A) Epoxide substrates were prepared starting from aromatic alcohols and alkenes as according to previously literatures procedure.³⁻⁸

(B) 2, 2-disubstituted epoxides were prepared according to literatures,⁹⁻¹⁰ the method has modified as followed:




In dried and cleaned round bottom flask, charged with trimethylsulfoxonium iodide (15 mmol, 1.5 equiv.) and potassium tertbutoxyde (1.5 equiv.). 15 mL of DMSO was added, then at room temperature the reaction mixture was stirred for 30 min. A solution of ketone (10 mmol, 1 equiv.) in DMSO (5 mL) was added. The reaction was left to react for more than 8 h at 50 - 60°C. After reaction complete, extracted from water by EtOAc, washed, dried, concentrated and purified by column chromatography.

Characterization of epoxides




2-((4-methoxyphenoxy)methyl)oxirane (CAS: 2211-94-1)

This compound was perviously reported and our spectra data match those described.⁷ following general procedure A. ¹H NMR (400 MHz, CDCl₃) δ 6.88 – 6.80 (m, 4H), 4.16 (dd, *J* = 11.0, 3.2 Hz, 1H), 3.89 (dd, *J* = 11.1, 5.7 Hz, 1H), 3.76 (s, 3H), 3.33 (ddt, *J* = 5.8, 3.9, 3.0 Hz, 1H), 2.88 (t, *J* = 4.5 Hz, 1H), 2.73 (dd, *J* = 4.9, 2.7 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 154.18, 152.65, 115.71, 114.64, 69.52, 55.69, 50.26, 44.71.




2-((3-methoxyphenoxy)methyl)oxirane (CAS: 2210-75-5)

Following general procedure A. ¹H NMR (400 MHz, CDCl₃) δ 7.21 – 7.14 (m, 1H), 6.56 – 6.46 (m, 3H), 4.20 (dd, *J* = 11.0, 3.2 Hz, 1H), 3.97 – 3.88 (m, 1H), 3.78 (s, 3H), 3.34 (ddt, *J* = 5.8, 4.1, 3.0 Hz, 1H), 2.92 – 2.87 (m, 1H), 2.74 (dd, *J* = 4.9, 2.7 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 160.84, 159.70, 129.94, 106.84, 106.62, 101.15, 68.74, 55.26, 50.10, 44.71.




2-((1,1'-biphenyl)-2-yloxy)methyl)oxirane (CAS: 7144-65-2)


Following general procedure A. ^1H NMR (400 MHz, CDCl_3) δ 7.54 (dt, $J = 4.2, 2.3$ Hz, 2H), 7.44 – 7.37 (m, 2H), 7.37 – 7.26 (m, 3H), 7.06 (tt, $J = 7.5, 1.1$ Hz, 1H), 6.98 (d, $J = 8.2$ Hz, 1H), 4.20 (dd, $J = 11.2, 2.6$ Hz, 1H), 3.97 (dd, $J = 11.2, 5.1$ Hz, 1H), 3.30 – 3.20 (m, 1H), 2.82 – 2.76 (m, 1H), 2.66 (dd, $J = 5.0, 2.6$ Hz, 1H). ^{13}C NMR (75 MHz, CDCl_3) δ 155.39, 138.29, 131.27, 131.02, 129.53, 128.60, 127.95, 126.93, 121.67, 113.18, 68.99, 50.21, 44.59.

**2-((2-fluorophenoxy)methyl)oxirane (CAS: 15620-80-1)**


Following general procedure A. ^1H NMR (400 MHz, CDCl_3) δ 7.12 – 7.04 (m, 2H), 7.04 – 6.96 (m, 1H), 6.96 – 6.88 (m, 1H), 4.28 (dd, $J = 11.2, 3.2$ Hz, 1H), 4.08 – 3.98 (m, 1H), 3.41 – 3.33 (m, 1H), 2.90 (td, $J = 4.5, 2.3$ Hz, 1H), 2.76 (dt, $J = 4.8, 2.2$ Hz, 1H). ^{19}F NMR (376 MHz, CDCl_3) δ -133.96 – -134.08 (m). ^{13}C NMR (101 MHz, CDCl_3) δ 152.86 (d, $J = 245.9$ Hz), 146.56 (d, $J = 10.6$ Hz), 124.36 (d, $J = 3.9$ Hz), 121.93 (d, $J = 6.9$ Hz), 116.38 (d, $J = 18.3$ Hz), 115.75, 70.40, 50.08, 44.64.

**4-(oxiran-2-ylmethoxy)phenyl acetate (CAS: 172210-35-4)**


Following general procedure A. ^1H NMR (400 MHz, CDCl_3) δ 8.04 – 7.95 (m, 2H), 6.99 – 6.89 (m, 2H), 4.34 – 4.26 (m, 1H), 3.97 (dd, $J = 11.0, 5.8$ Hz, 1H), 3.93 – 3.85 (m, 3H), 3.36 (ddt, $J = 5.8, 4.1, 2.8$ Hz, 1H), 2.97 – 2.88 (m, 1H), 2.76 (dd, $J = 4.9, 2.6$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 166.73, 162.14, 131.62, 123.11, 114.19, 68.82, 51.90, 49.90, 44.58.

**2-((4-chlorophenoxy)methyl)oxirane (CAS: 2212-05-7)**

This compound was perviously reported and our spectra data match those described.¹¹⁻¹² Following general procedure A. ^1H NMR (400 MHz, CDCl_3) δ 7.25 – 7.19 (m, 2H), 6.88 – 6.81 (m, 2H), 4.21 (dd, $J = 11.0, 3.0$ Hz, 1H), 3.93 – 3.85 (m, 1H), 3.33 (ddt, $J = 5.8, 4.0, 2.8$ Hz, 1H), 2.90 (t, $J = 4.5$ Hz, 1H), 2.74 (dd, $J = 4.9, 2.6$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 157.09, 129.37, 126.09, 115.94, 69.06, 50.02, 44.56.


**2-((4-iodophenoxy)methyl)oxirane (CAS: 828-25-1)**

Following general procedure A. ^1H NMR (400 MHz, CDCl_3) δ 7.60 – 7.49 (m, 2H), 6.74 – 6.64 (m, 2H), 4.20 (ddd, $J = 11.0, 2.9, 1.9$ Hz, 1H), 3.94 – 3.84 (m, 1H), 3.37 – 3.28 (m, 1H), 2.93 – 2.85 (m, 1H), 2.74 (dt, $J = 5.0, 2.6$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 158.38, 138.29, 117.05, 83.43, 68.86, 49.99, 44.61.




2-((naphthalen-2-yloxy)methyl)oxirane (CAS: 5234-06-0)

This compound was perviously reported and our spectra data match those described.¹³ Following general procedure A. ¹H NMR (400 MHz, CDCl₃) δ 7.79 – 7.69 (m, 3H), 7.44 (t, *J* = 7.1 Hz, 1H), 7.37 – 7.31 (m, 1H), 7.18 (dt, *J* = 8.7, 4.4 Hz, 1H), 7.13 (d, *J* = 2.5 Hz, 1H), 4.34 (dd, *J* = 11.0, 3.1 Hz, 1H), 4.07 (dd, *J* = 11.0, 5.7 Hz, 1H), 3.48 – 3.37 (m, 1H), 2.99 – 2.89 (m, 1H), 2.81 (dd, *J* = 4.9, 2.7 Hz, 1H).¹³C NMR (101 MHz, CDCl₃) δ 156.42, 134.40, 129.54, 129.16, 127.66, 126.79, 126.45, 123.85, 118.78, 106.84, 68.73, 50.11, 44.78.




2-((4-methoxyphenoxy)methyl)-2-methyloxirane (CAS: 892390-16-8)

Following general procedure A. ¹H NMR (400 MHz, CDCl₃) δ 6.88 – 6.79 (m, 4H), 3.98 (d, *J* = 10.5 Hz, 1H), 3.90 (d, *J* = 10.5 Hz, 1H), 3.76 (s, 3H), 2.86 (d, *J* = 4.8 Hz, 1H), 2.72 (d, *J* = 4.8 Hz, 1H), 1.48 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 154.10, 152.82, 115.67, 114.61, 72.25, 55.70, 55.64, 52.03, 18.50.




2-methyl-2-((naphthalen-2-yloxy)methyl)oxirane (CAS: 85686-31-3)

Following general procedure A. ¹H NMR (400 MHz, CDCl₃) δ 7.74 (dd, *J* = 18.0, 8.7 Hz, 3H), 7.47 – 7.39 (m, 1H), 7.34 (ddd, *J* = 11.0, 6.0, 2.6 Hz, 1H), 7.21 – 7.16 (m, 1H), 7.13 (d, *J* = 2.4 Hz, 1H), 4.15 (d, *J* = 10.4 Hz, 1H), 4.06 (d, *J* = 10.4 Hz, 1H), 2.93 (d, *J* = 4.7 Hz, 1H), 2.77 (d, *J* = 4.7 Hz, 1H), 1.53 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 156.56, 134.44, 129.50, 129.15, 127.67, 126.81, 126.45, 123.83, 118.82, 106.92, 71.48, 55.57, 52.12, 18.60.




2-(4-methoxybenzyl)oxirane (CAS: 51410-45-8)

This compound was perviously reported and our spectra data match those described.¹⁴ ¹H NMR (400 MHz, CDCl₃) δ 7.19 – 7.13 (m, 2H), 6.88 – 6.82 (m, 2H), 3.79 (s, 3H), 3.15 – 3.06 (m, 1H), 2.86 (dd, *J* = 14.6, 5.6 Hz, 1H), 2.80 – 2.70 (m, 2H), 2.52 (dd, *J* = 5.0, 2.7 Hz, 1H).¹³C NMR (101 MHz, CDCl₃) δ 158.43, 129.99, 129.14, 113.95, 55.26, 52.61, 46.80, 37.82.




N-(oxiran-2-ylmethyl)-N-phenylaniline (CAS: 4510-27-4)

This compound was perviously reported and our spectra data match those described.¹⁵ ¹H NMR (400 MHz, CDCl₃) δ 7.31 – 7.23 (m, 4H), 7.04 (d, *J* = 7.7 Hz, 4H), 6.97 (t, *J* = 7.3 Hz, 2H), 3.96 (dd, *J* = 15.8, 3.8 Hz, 1H), 3.86 (dd, *J* = 15.8, 4.8 Hz, 1H), 3.23 (td, *J* = 7.1, 4.0 Hz, 1H), 2.80 – 2.75 (m, 1H), 2.56 (dd, *J* = 4.9, 2.7 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 147.95, 129.37, 121.72, 121.02, 53.87, 50.37, 46.01.




2-(((2-bromophenyl)thio)methyl)oxirane (CAS: 1094686-08-4)

¹H NMR (400 MHz, CDCl₃) δ 7.57 (dd, *J* = 8.0, 1.0 Hz, 1H), 7.41 (dd, *J* = 7.9, 1.4 Hz, 1H), 7.31 – 7.27 (m, 1H), 7.08 (td, *J* = 7.9, 1.6 Hz, 1H), 3.24 – 3.16 (m, 2H), 3.06 – 2.97 (m, 1H), 2.80 (t, *J* = 4.3 Hz, 1H), 2.58 (dd, *J* = 4.9, 2.4 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 136.64, 133.19, 129.78, 127.88, 127.56, 124.70, 50.59, 47.27, 35.70.




2-((2-bromo-4-chlorophenoxy)methyl)oxirane (CAS: 68224-01-1)

This compound was perviously reported and our spectra data match those described.¹⁰ ¹H NMR (400 MHz, CDCl₃) δ 7.54 (d, *J* = 2.5 Hz, 1H), 7.22 (dd, *J* = 8.8, 2.5 Hz, 1H), 6.86 (d, *J* = 8.8 Hz, 1H), 4.30 (dd, *J* = 11.3, 2.8 Hz, 1H), 4.02 (dd, *J* = 11.2, 5.3 Hz, 1H), 3.41 – 3.32 (m, 1H), 2.92 (t, *J* = 4.5 Hz, 1H), 2.84 (dd, *J* = 4.9, 2.6 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 153.84, 132.97, 128.32, 126.80, 114.51, 112.97, 69.96, 49.97, 44.55.




Benzyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (CAS: 77211-75-7)

This compound was perviously reported and our spectra data match those described.¹⁰ Following general procedure B. ¹H NMR (400 MHz, CDCl₃) δ 7.40 – 7.28 (m, 5H), 5.15 (s, 2H), 3.82 (s, 2H), 3.49 (ddd, *J* = 13.3, 9.7, 3.6 Hz, 2H), 2.70 (s, 2H), 1.83 (s, 2H), 1.45 (d, *J* = 12.6 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 155.26, 136.72, 128.52, 128.05, 127.92, 67.24, 56.93, 53.74, 42.66, 32.89.




5-((2-(2-methyloxiran-2-yl)ethyl)benzo[d][1,3]dioxole (CAS: 1644661-06-2)

This compound was perviously reported and our spectra data match those described.¹⁰ Following general procedure B. ¹H NMR (300 MHz, CDCl₃) δ 6.76 – 6.59 (m, 3H), 5.92 (s, 2H), 2.70 – 2.54 (m, 4H), 1.94 – 1.71 (m, 2H), 1.36 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 147.61, 145.70, 135.43, 120.96, 108.73, 108.20, 100.80, 56.62, 53.92, 38.81, 31.18, 21.04.



2-((2-(thiophen-2-yl)ethoxy)methyl)oxirane (CAS: 1250057-30-7)

This compound was perviously reported and our spectra data match those described.¹⁰ ¹H NMR (400 MHz, CDCl₃) δ 7.14 (dd, *J* = 5.1, 1.2 Hz, 1H), 6.92 (dt, *J* = 8.2, 4.1 Hz, 1H), 6.87 – 6.83 (m, 1H), 3.82 – 3.66 (m, 3H), 3.42 (dt, *J* = 11.2, 5.6 Hz, 1H), 3.19 – 3.14 (m, 1H), 3.11 (t, *J* = 6.8 Hz, 2H), 2.82 – 2.77 (m, 1H), 2.62 (dd, *J* = 5.0, 2.7 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 141.06, 126.70, 125.18, 123.69, 72.01, 71.56, 50.81, 44.27, 30.45.



2-butyl-1-tosylaziridine (CAS: 116905-61-4)

This compound was perviously reported and our spectra data match those described.¹⁰ ¹H NMR (300 MHz, CDCl₃) δ 7.83 (d, *J* = 8.2 Hz, 2H), 7.34 (d, *J* = 8.0 Hz, 2H), 2.78 – 2.67 (m, 1H), 2.63 (d, *J* = 7.0 Hz, 1H), 2.45 (s, 3H), 2.07 (t, *J* = 6.7 Hz, 1H), 1.61 – 1.48 (m, 1H), 1.35 (dt, *J* = 13.5, 6.9 Hz, 1H), 1.29 – 1.13 (m, 4H), 0.81 (t, *J* = 6.8 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 144.41, 135.23, 129.62, 128.00, 40.43, 33.82, 31.00, 28.88, 22.12, 21.63, 13.84.

III. General Experimental Procedures, Spectral Data and HPLC

Analysis

Experimental Procedures for Examples Described in Table 1.

In air, clean and dried schlenk tube was charged with Cu catalyst (0.04 mmol), base (0.6 mmol, 3 equiv.), and diborylmethane (0.4 mmol, 2 equiv.) which equipped with a stirring bar. The vessel was evacuated and filled with argon (three times). Under inert gas 0.5 mL of solvent was added. The reaction mixture was stirred for 10 – 20 min at 60 °C. Then benzyl glycidyl ether substrate (0.2 mmol, 1 equiv.) was added under inert gas. The resulting suspension was stirred for 24 h at 60 °C. After completing of reaction, 4 mL of H₂O was added for reaction mixture, and extracted by EtOAc (3 x 5 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure and purified by flash column chromatography over silic gel using petroleum ether/EtOAc (10/1 to 5/1, v/v) as eluent. The column fractions were collected together and evaporated under reduced pressure to obtain the desired product.

Experimental Procedures for Examples Described in Table 2.

In air, schlenk tube was charged with CuI (0.04 mmol), LiO^tBu (0.6 mmol, 3 equiv.), and diborylmethane (0.4 mmol, 2 equiv.) which equipped with a stirring bar. The vessel was evacuated and filled with argon (three times). Under inert gas 0.5 mL of THF was added. The reaction mixture was stirred for 20 min at 60 °C. Then oxirane substrate (0.2 mmol, 1 equiv.) was added under inert gas. The resulting suspension was stirred for 24 h at 60 °C. After completing of reaction, 4 mL of H₂O was added for reaction mixture, and extracted by EtOAc (3 x 5 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure and purified by flash column chromatography using petroleum ether/EtOAc (10/1 to 2/1,

v/v) as eluent to afford the desired product.

Experimental Procedures for Examples Described in Table 3.

In air, schlenk tube was charged with CuI (0.04 mmol), LiO^tBu (0.6 mmol, 3 equiv.), and diborylmethane (0.4 mmol, 2 equiv.) which equipped with a stirring bar. The vessel was evacuated and filled with argon (three times). Under inert gas 0.5 mL of THF was added. The reaction mixture was stirred for 20 min at 60 °C. Then 1,1-disubstituted epoxide substrate (0.2 mmol, 1 equiv.) was added under inert gas. The resulting suspension was stirred for 24 h at 60 or 80 °C (ketal group substrate, the reaction was performed at 80 °C). After completing of reaction, 4 mL of H₂O was added for reaction mixture, and extracted by EtOAc (3 x 5 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure followed by flash column chromatography using petroleum ether/EtOAc (10/1 to 3/1, v/v) as eluent to afford the desired product.

Experimental Procedures for Examples Described in Scheme 2.


In air, schlenk tube was charged with CuI (0.04 mmol), LiO^tBu (0.6 mmol, 3 equiv.), and diborylmethane (0.4 mmol, 2 equiv.) which equipped with a stirring bar. The vessel was evacuated and filled with argon (three times). Under inert gas 0.5 mL of THF was added. The reaction mixture was stirred for 15 min at 60 °C. Then N-sulfonyl aziridine (0.2 mmol, 1 equiv.) was added under inert gas. The resulting suspension was stirred for 24 h at 60 °C up to end of reaction. The resulting reaction mixture was filtered, concentrated under reduced pressure and purified by flash column chromatography using petroleum ether/EtOAc (5/1, v/v) as eluent to afford the desired product.

Experimental Procedures for Examples Described in Scheme 3.

- A) In air, schlenk tube was charged with CuI (0.04 mmol), LiO^tBu (0.6 mmol, 3 equiv.), and diborylmethane (0.4 mmol, 2 equiv.) which equipped with a stirring bar. The vessel was evacuated and filled with argon (three times). Under inert gas 0.5 mL of THF was added. The reaction mixture was stirred for 20 min at 60 °C. Then benzyl (S)-glycidyl ether (0.2 mmol, 1 equiv.) was added under inert gas. The resulting suspension was stirred for 24 h at 60 °C. After completing of reaction, 4 mL of H₂O was added for reaction mixture, extracted by EtOAc (3 x 5 mL), dried over anhydrous Na₂SO₄, filtered, concentrated and purified by flash column chromatography using petroleum ether/EtOAc (5/1, v/v) as eluent to afford γ -pinacolboronate alcohol product.
- B) The oxidation step of pinacolboronate alcohol was conducted according to the previous literatures procedure.¹⁶⁻¹⁸ In around-bottom flask, γ -pinacolboronate alcohol (0.13 mmol) in 4 mL THF was cooled to 0 °C (ice-water bath), and 0.65 mL of 3 N NaOH and 0.65 mL of 30% H₂O₂ were added dropwise. The mixture was then stirred at ambient temperature for 8 h. 2 mL of water was added to the resulting solution, and then extracted by EtOAc (3 x 5 mL), dried over anhydrous Na₂SO₄, filtered, concentrated and purified by column chromatography using petroleum ether/EtOAc (2/1, v/v) to afford 1,3-diol product. The enantiomeric purity of (S)-4-(benzyloxy)butane-1,3-diol was determined by HPLC analysis in comparison with racemic product (Chiralcel OD-H column, 90:10 hexanes/*i*-PrOH, 1.5

mL/min, 210 nm).


Substrate scope



Phenoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (3a)

Following general procedure, (49.5 mg, 85% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.32 – 7.21 (m, 2H), 6.98 – 6.83 (m, 3H), 3.99 – 3.89 (m, 2H), 3.88 – 3.73 (m, 1H), 2.75 (br, 1H), 1.87 – 1.59 (m, 2H), 1.24 (s, 12H), 0.99 – 0.85 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 158.70, 129.42, 120.87, 114.54, 83.19, 71.83, 71.52, 27.61, 24.79, 7.06.


HRMS calcd for $\text{C}_{16}\text{H}_{25}\text{BO}_4[\text{H}]^+$: 293.1919; found: 293.1913.



1-(4-methoxyphenoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (3b)

Following general procedure, (52 mg, 81% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 6.81 – 6.68 (m, 4H), 3.88 – 3.80 (m, 2H), 3.76 – 3.70 (m, 1H), 3.68 (s, 3H), 2.40 (br, 1H), 1.75 – 1.50 (m, 2H), 1.25 (s, 12H), 0.94 – 0.75 (m, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ 154.07, 152.99, 115.64, 114.73, 83.34, 72.78, 71.79, 55.81, 27.66, 24.91, 7.17.


HRMS calcd for $\text{C}_{17}\text{H}_{27}\text{BO}_5[\text{H}]^+$: 323.2024; found: 323.2027.



1-(3-methoxyphenoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (3c)

Following general procedure, (35.8 mg, 56% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.23 – 7.07 (m, 1H), 6.61 – 6.35 (m, 3H), 4.00 – 3.89 (m, 2H), 3.89 – 3.80 (m, 1H), 3.78 (s, 3H), 2.57 (br, 1H), 1.86 – 1.56 (m, 2H), 1.25 (s, 12H), 1.03 – 0.84 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 160.92, 160.07, 130.00, 106.78, 106.73, 101.16, 83.39, 72.05, 71.73, 55.38, 27.68, 24.92, 7.28.

HRMS calcd for $\text{C}_{17}\text{H}_{27}\text{BO}_5[\text{H}]^+$: 323.2024; found: 323.2029.




1-(4-chlorophenoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (3d)

Following general procedure, (53 mg, 81% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.25 – 7.19 (m, 2H), 6.86 – 6.79 (m, 2H), 3.98 – 3.88 (m, 2H), 3.86 – 3.77 (m, 1H), 2.45 (br, 1H), 1.83 –

1.57 (m, 2H), 1.25 (s, 12H), 1.01 – 0.86 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 157.46, 129.43, 125.91, 115.95, 83.44, 72.36, 71.68, 27.68, 24.92, 7.20.


HRMS calcd for $\text{C}_{16}\text{H}_{24}\text{BClO}_4[\text{H}]^+$: 327.1529; found: 327.1531.



1-(2-fluorophenoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (3e)

Following general procedure, (48.5 mg, 78% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.14 – 7.00 (m, 2H), 6.99 – 6.84 (m, 2H), 4.20 – 3.68 (m, 3H), 2.61 (br, 1H), 1.85 – 1.57 (m, 2H), 1.25 (s, 12H), 1.03 – 0.84 (m, 2H). ^{19}F NMR (376 MHz, CDCl_3) δ -134.26 – -134.55 (m). ^{13}C NMR (101 MHz, CDCl_3) δ 152.90 (d, J = 245.6 Hz), 146.94 (d, J = 10.6 Hz), 124.41 (d, J = 3.9 Hz), 121.56 (d, J = 6.9 Hz), 116.35 (d, J = 18.2 Hz), 115.41 (d, J = 1.6 Hz), 83.38, 73.58, 71.62, 27.50, 24.91, 7.12.


HRMS calcd for $\text{C}_{16}\text{H}_{24}\text{BFO}_4[\text{H}]^+$: 311.1824; found: 311.1827.



1-(4-iodophenoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (3f)

Following general procedure, (55.8 mg, 67% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.58 – 7.49 (m, 2H), 6.74 – 6.62 (m, 2H), 3.99 – 3.86 (m, 2H), 3.86 – 3.76 (m, 1H), 2.58 (br, 1H), 1.80 – 1.58 (m, 2H), 1.25 (s, 12H), 1.01 – 0.81 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 158.72, 138.31, 117.07, 83.42, 83.12, 72.14, 71.61, 27.67, 24.92, 7.15.


HRMS calcd for $\text{C}_{16}\text{H}_{24}\text{BIO}_4[\text{H}]^+$: 419.0885; found: 419.0889.



Methyl 4-(2-hydroxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butoxy)benzoate (3g)

Following general procedure, (51.2 mg, 73% yield) as a white solid. ^1H NMR (300 MHz, CDCl_3) δ 7.98 (d, J = 8.8 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 4.08 – 3.91 (m, 3H), 3.89 (s, 3H), 1.79 – 1.63 (m, 2H), 1.26 (s, 12H), 0.95 (t, J = 7.6 Hz, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 166.96, 162.61, 131.72, 122.94, 114.28, 83.48, 72.19, 71.64, 52.01, 27.70, 24.94, 7.20.


HRMS calcd for $\text{C}_{18}\text{H}_{27}\text{BO}_6[\text{H}]^+$: 351.1973; found: 351.1978.



1-([1,1'-biphenyl]-2-yloxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (3h)

Following general procedure, (49.8 mg, 68% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.54 – 7.47 (m, 2H), 7.43 – 7.36 (m, 2H), 7.35 – 7.26 (m, 3H), 7.07 – 7.02 (m, 1H), 6.99 – 6.93 (m, 1H), 4.01 – 3.90 (m, 1H), 3.89 – 3.75 (m, 2H), 2.24 (br, 1H), 1.70 – 1.51 (m, 2H), 1.23 (s, 12H), 0.94 – 0.69 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.60, 138.54, 131.44, 130.98, 129.56, 128.77, 128.16, 127.08, 121.55, 113.24, 83.29, 72.80, 71.65, 27.47, 24.92, 7.23.


HRMS calcd for $C_{22}H_{29}BO_4[H]^+$: 369.2232; found: 369.2242.



1-(2-bromo-4-chlorophenoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (3i)

Following general procedure, (58 mg, 72% yield) as a colorless oil. 1H NMR (400 MHz, $CDCl_3$) δ 7.58 – 7.45 (m, 1H), 7.25 – 7.17 (m, 1H), 6.81 (d, J = 8.8 Hz, 1H), 4.03 – 3.94 (m, 2H), 3.93 – 3.81 (m, 1H), 2.68 (br, 1H), 1.88 – 1.63 (m, 2H), 1.26 (s, 12H), 1.06 – 0.85 (m, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 154.04, 132.87, 128.42, 126.50, 114.29, 112.97, 83.40, 73.64, 71.50, 27.50, 24.92, 7.26.


HRMS calcd for $C_{16}H_{23}BBrClO_4[H]^+$: 405.0634; found: 405.0637.



1-(benzyloxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (3j)

Following general procedure, (41 mg, 67% yield) as a colorless oil. 1H NMR (400 MHz, $CDCl_3$) δ 7.39 – 7.27 (m, 5H), 4.61 – 4.50 (m, 2H), 3.86 – 3.63 (m, 1H), 3.53 – 3.45 (m, 1H), 3.43 – 3.28 (m, 1H), 2.42 (br, 1H), 1.66 – 1.51 (m, 2H), 1.24 (s, 12H), 0.93 – 0.80 (m, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 138.20, 128.51, 127.82, 127.79, 83.23, 74.46, 73.38, 72.05, 27.64, 24.89, 7.25.


HRMS calcd for $C_{17}H_{27}BO_4[H]^+$: 307.2075; found: 307.2073.



1-(naphthalen-2-yloxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (3k)

Following general procedure, (53.9 mg, 79% yield) as a white solid. 1H NMR (400 MHz, $CDCl_3$) δ 7.77 – 7.67 (m, 3H), 7.45 – 7.39 (m, 1H), 7.35 – 7.30 (m, 1H), 7.16 (dd, J = 8.9, 2.5 Hz, 1H), 7.12 (d, J = 2.5 Hz, 1H), 4.11 – 3.94 (m, 3H), 2.46 (br, 1H), 1.87 – 1.65 (m, 2H), 1.25 (s, 12H), 1.03 – 0.90 (m, 2H). ^{13}C NMR (75 MHz, $CDCl_3$) δ 156.77, 134.60, 129.51, 129.16, 127.74, 126.87, 126.48, 123.79, 118.94, 106.93, 83.39, 72.08, 71.74, 27.78, 24.93, 7.11.


HRMS calcd for $C_{20}H_{27}BO_4[H]^+$: 343.2075; found: 343.2077.



1-(4-methoxyphenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (3l)

Following general procedure, (48.5 mg, 79% yield) as a colorless oil. 1H NMR (400 MHz, $CDCl_3$) δ 7.17 – 7.08 (m, 2H), 6.88 – 6.79 (m, 2H), 3.78 (s, 3H), 3.76 – 3.66 (m, 1H), 2.80 – 2.68 (m, 1H), 2.68 – 2.56 (m, 1H), 1.74 – 1.63 (m, 1H), 1.60 – 1.53 (m, 1H), 1.24 (s, 12H), 0.95 – 0.85 (m, 2H). ^{13}C NMR (75 MHz, $CDCl_3$) δ 158.27, 131.03, 130.45, 114.02, 83.33, 74.62, 55.40, 42.94, 31.00, 24.95.


HRMS calcd for $C_{17}H_{27}BO_4[H]^+$: 307.2075 found: 307.2079.



4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2-(thiophen-2-yl)ethoxy)butan-2-ol (3m)


Following general procedure, (50 mg, 77% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.21 – 7.05 (m, 1H), 6.99 – 6.87 (m, 1H), 6.86 – 6.77 (m, 1H), 3.78 – 3.62 (m, 3H), 3.56 – 3.43 (m, 1H), 3.32 (dd, $J = 9.5, 7.6$ Hz, 1H), 3.20 – 3.01 (m, 2H), 2.35 (br, 1H), 1.69 – 1.47 (m, 2H), 1.24 (s, 12H), 0.96 – 0.77 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 141.30, 126.77, 125.25, 123.83, 83.24, 75.11, 71.95, 71.83, 30.52, 27.55, 24.90, 7.06.

HRMS calcd for $\text{C}_{16}\text{H}_{27}\text{BO}_4\text{S}[\text{H}]^+$: 327.1796; found: 327.1796.

**1-(diphenylamino)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (3n)**


Following general procedure, (51.1 mg, 70% yield) as light brown oil. ^1H NMR (400 MHz, CDCl_3) δ 7.30 – 7.22 (m, 4H), 7.07 (d, $J = 7.7$ Hz, 4H), 6.97 (t, $J = 7.3$ Hz, 2H), 3.92 – 3.78 (m, 2H), 3.69 – 3.60 (m, 1H), 1.76 – 1.52 (m, 2H), 1.24 (s, 12H), 0.90 (t, $J = 7.6$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ 148.64, 129.43, 121.83, 121.54, 83.34, 70.57, 58.98, 28.87, 24.94.

HRMS calcd for $\text{C}_{22}\text{H}_{30}\text{BNO}_3[\text{H}]^+$: 368.2392; found: 368.2388.

**1-(2-bromophenylthio)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (3o)**


Following general procedure, (62.2 mg, 81% yield) as pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.56 – 7.54 (m, 1H), 7.35 – 7.33 (m, 1H), 7.28 – 7.24 (m, 1H), 7.06 – 7.02 (m, 1H), 3.70 (tt, $J = 8.1, 4.0$ Hz, 1H), 3.12 (dd, $J = 13.4, 4.0$ Hz, 1H), 2.93 (dd, $J = 13.4, 8.2$ Hz, 1H), 1.83 – 1.60 (m, 2H), 1.23 (s, 12H), 0.91 (t, $J = 7.6$ Hz, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 137.33, 133.17, 129.14, 127.88, 127.10, 124.37, 83.37, 71.10, 40.87, 30.65, 24.90, 7.54.

HRMS calcd for $\text{C}_{16}\text{H}_{24}\text{BBro}_3\text{S}[\text{H}]^+$: 387.0795; found: 387.0801.

**1-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propan-1-ol (3p)**

Following general procedure, (30 mg, 57% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.37 – 7.31 (m, 3H), 7.30 – 7.23 (m, 2H), 4.64 (t, $J = 6.4$ Hz, 1H), 2.28 (br, 1H), 1.90 – 1.84 (m, 2H), 1.24 (s, 12H), 0.91 – 0.75 (m, 1H). ^{13}C NMR (75 MHz, CDCl_3) δ 144.84, 128.42, 127.39, 126.01, 83.36, 76.09, 33.63, 24.94.


HRMS calcd for $\text{C}_{15}\text{H}_{23}\text{BO}_3[\text{H}]^+$: 263.1813; found: 263.1807.



1-(4-methoxyphenoxy)-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (3ba)

Following general procedure, (49.5 mg, 74% yield) as pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 6.88 – 6.78 (m, 4H), 3.78 – 3.71 (m, 5H), 1.86 – 1.77 (m, 1H), 1.74 – 1.64 (m, 1H), 1.25 (s, 12H), 1.24 (s, 3H), 0.93 – 0.81 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 154.06, 153.23, 115.67, 114.74, 83.34, 75.56, 72.40, 55.89, 32.97, 24.96, 23.56.


HRMS calcd for $\text{C}_{18}\text{H}_{29}\text{BO}_5[\text{H}]^+$: 337.2181; found: 337.2183.



2-methyl-1-(naphthalen-2-yloxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (3bb)

Following general procedure, (42 mg, 59% yield) as pale yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.79 – 7.69 (m, 3H), 7.46 – 7.41 (m, 1H), 7.36 – 7.31 (m, 1H), 7.18 (dd, $J = 8.8, 2.5$ Hz, 1H), 7.15 – 7.12 (m, 1H), 3.93 (q, $J = 8.9$ Hz, 2H), 1.93 – 1.83 (m, 1H), 1.80 – 1.71 (m, 1H), 1.32 (s, 3H), 1.26 (s, 12H), 0.99 – 0.86 (m, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ 156.95, 134.65, 129.49, 129.19, 127.77, 126.90, 126.51, 123.81, 119.05, 106.98, 83.39, 74.87, 72.39, 33.07, 24.97, 23.70.


HRMS calcd for $\text{C}_{21}\text{H}_{29}\text{BO}_4[\text{H}]^+$: 357.2232; found: 357.2235.



Benzyl 4-hydroxy-4-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-1-carboxylate (3bc)

Following general procedure, (52.7 mg, 68% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.40 – 7.28 (m, 5H), 5.12 (s, 2H), 3.90 (br, 2H), 3.23 (br, 2H), 1.67 – 1.42 (m, 6H), 1.25 (s, 12H), 0.83 (t, $J = 7.8$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ 155.41, 137.08, 128.58, 128.02, 127.92, 83.52, 69.77, 67.07, 40.25, 36.83, 36.58, 24.92, 4.05.


HRMS calcd for $\text{C}_{21}\text{H}_{32}\text{BNO}_5[\text{H}]^+$: 390.2446; found: 390.2448.



1-(benzo[d][1,3]dioxol-5-yl)-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentan-3-ol (3bd)

Following general procedure, (41.5 mg, 60% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 6.77 – 6.66 (m, 2H), 6.65 – 6.51 (m, 1H), 6.06 – 5.70 (m, 2H), 2.77 – 2.43 (m, 2H), 1.75 – 1.58 (m, 4H), 1.26 (s, 12H), 1.19 (s, 3H), 0.92 – 0.78 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 147.65, 145.59, 136.78, 121.06, 108.99, 108.28, 100.86, 83.38, 72.89, 44.09, 35.92, 30.29, 26.31, 24.95.


HRMS calcd for $\text{C}_{19}\text{H}_{29}\text{BO}_5[\text{H}]^+$: 349.2181; found: 349.2178.



4-methyl-N-(1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)heptan-3-yl)benzenesulfonamide (3ca)

Following general procedure, (62.5 mg, 79% yield) as off-white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.80 – 7.72 (m, 2H), 7.34 – 7.21 (m, 2H), 4.81 – 4.49 (m, 1H), 3.31 – 3.01 (m, 1H), 2.42 (s, 3H), 1.54 – 1.05 (m, 20H), 0.82 – 0.72 (m, 3H), 0.71 – 0.55 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 143.00, 138.62, 129.58, 127.17, 83.36, 55.56, 34.37, 28.70, 27.46, 24.86, 22.53, 13.99, 6.57.


HRMS calcd for $\text{C}_{20}\text{H}_{34}\text{BNO}_4\text{S}[\text{H}]^+$: 396.2374; found: 396.2372.



(S)-1-(benzyloxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butan-2-ol (3aa)

Following general procedure, (48.2 mg, 79% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.38 – 7.27 (m, 5H), 4.55 (s, 2H), 3.84 – 3.67 (m, 1H), 3.53 – 3.43 (m, 1H), 3.35 (dd, $J = 9.4, 7.6$ Hz, 1H), 2.35 (br, 1H), 1.69 – 1.49 (m, 2H), 1.24 (s, 12H), 0.93 – 0.77 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 138.22, 128.5, 127.82, 127.79, 83.24, 74.48, 73.40, 72.07, 27.65, 24.89, 7.27.


HRMS calcd for $\text{C}_{17}\text{H}_{27}\text{BO}_4[\text{H}]^+$: 307.2075; found: 307.2078.



(S)-4-(benzyloxy)butane-1,3-diol (3ab)

Following general procedure, (23.7 mg, 93% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.39 – 7.27 (m, 5H), 4.55 (s, 2H), 4.13 – 3.98 (m, 1H), 3.88 – 3.72 (m, 2H), 3.49 (dd, $J = 9.5, 3.6$ Hz, 1H), 3.44 – 3.37 (m, 1H), 2.64 (br, 2H), 1.78 – 1.60 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 137.93, 128.61, 127.99, 127.91, 74.51, 73.52, 70.27, 61.00, 34.98.

HRMS calcd for $\text{C}_{11}\text{H}_{16}\text{O}_3[\text{H}]^+$: 197.1172; found: 197.1166.




4-(benzyloxy)butane-1,3-diol (3ac)


Following general procedure, (21.9 mg, 86% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.39 – 7.27 (m, 5H), 4.55 (s, 2H), 4.12 – 3.98 (m, 1H), 3.89 – 3.73 (m, 2H), 3.49 (dd, $J = 9.5, 3.6$ Hz, 1H), 3.44 – 3.37 (m, 1H), 2.61 (br, 2H), 1.78 – 1.57 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 137.93, 128.61, 127.98, 127.90, 74.52, 73.52, 70.24, 60.97, 34.99.

HRMS calcd for $\text{C}_{11}\text{H}_{16}\text{O}_3[\text{H}]^+$: 197.1172; found: 197.1165.


HPLC Analysis




mV



Peak	Ret. Time (min)	Area ((mAu*s)	Height (mAU)	Area %
1	8.683	16619123	924154	49.598
2	11.506	16888831	713493	50.402



mV



Peak	Ret. Time (min)	Area ((mAu*s)	Height (mAU)	Area %
1	8.761	167134	6637	0.422
2	11.442	39450314	1534364	99.578

IV. References

- (1) C. Yang, Z. Zhang, H. Tajuddin, C. Wu, J. Liang, J. Liu, Y. Fu, M. Czyzewska, P. Steel, T. Marder, and L. Liu, *Angew. Chem. Int. Ed.*, 2012, **51**, 528.
- (2) Z. Zhang, C. Yang, L. Liang, B. Xiao, X. Lu, J. Liu, Y. Sun, T. Marder, Y. Fu, *Org. Lett.*, 2014, **16**, 6342.
- (3) S. Tasler, R. Baumgartner, A. Ammendola, J. Schachtner, T. Wieber, M. Blisse, S. Rath, M. Zaja, P. Klahn, U. Quotschalla, P. Ney, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 6108.
- (4) C. Tacon, E. Guantai, P. Smith, K. Chibale, *Bioorg. Med. Chem.*, 2012, **20**, 893.
- (5) D. Taber, C. Paquette, P. Gu, W. Tian, *J. Org. Chem.*, 2013, **78**, 9772.
- (6) D. Limnios, C. Kokotos, *J. Org. Chem.*, 2014, **79**, 4270.
- (7) R. Panchadhayee, and A. K. Misra, *Arkivoc (Gainesville, FL, United States)*, 2008, 298.
- (8) D. S. Shapenova, M. K. Belyatskii, and L. P. Panicheva, *Russ. J. Org. Chem.*, 2010, **46**, 1017 and references therein.
- (9) J. Ciaccio, A. Drahus, R. Meis, C. Tingle, M. Smrtka, R. Geneste, *Synth. Commun.*, 2003, **33**, 2135.
- (10) X. Lu, C. Yang, J. Liu, Z. Zhang, X. Lu, X. Lou, B. Xiao and Y. Fu *Chem. Commun.*, 2015, **51**, 2388.
- (11) B.K. Pchelka, A. Loupy, and A. Petit, *Tetrahedron*, 2006, **62**, 10968.
- (12) D. E. Bevan, T. E. Mollnes, and H. Yin, *J. Med. Chem.*, 2011, **54**, 4659.
- (13) A. Fagerström, M. Nilsson, U. Berg, and R. Isaksson, *Org. Biomol. Chem.*, 2006, **4**, 3067.
- (14) H. S. He, C. Zhang, C. Ng, and P. H. Toy, *Tetrahedron*, 2005, **61**, 12053.
- (15) P. Wipf, and J. P. Maciejewski, *Org. Lett.*, 2008, **10**, 4383.
- (16) H. Y. Cho and J. P. Morken, *J. Am. Chem. Soc.*, 2008, **130**, 16140.
- (17) H. Y. Cho and J. P. Morken, *J. Am. Chem. Soc.*, 2010, **132**, 7576.
- (18) T. P. Blaisdell, T. C. Caya, L. Zhang, A. Sanz-Marco, and J. P. Morken, *J. Am. Chem. Soc.*, 2014, **136**, 9264.

V. NMR Spectra

